Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib (NASDAQ:KZIA)
· seekingalpha.com
Kazia Therapeutics' pipeline is validated by recent PI3K/AKT/mTOR pathway approvals and acquisitions.. Read more on KZIA stock here.
I am working in the financial sector. My areas of interest are technology, biotech, pharmaceutical companies, banks and a bit of shipping when an actionable tra...